Pharmaceuticals
Eleva Reaches Industrial Production Scale and Prepares for Clinical Development of Factor H
FREIBURG, Germany, Sept. 14, 2021 /PRNewswire/ -- Eleva, a manufacturer of superior biologics, is scaling up its production capacity to 2500 l in state-of-the-art single-use reactors. This will produce enough factor H to cover all three clinical phases. Eleva has ordered four more state-of-the-a...
2021-09-14 10:30
2304
CStone presents updated data from registrational clinical study of sugemalimab in patients with stage IV NSCLC in an oral presentation at IASLC 2021 WCLC
* Data with the longer follow-up showed that sugemalimab plus chemotherapy continued to demonstrate improvement in progression-free survival (PFS), after the primary efficacy endpoint was met at an interim PFS analysis last year * The updated data showed that the risk of disease progression or...
2021-09-14 08:30
5320
Global Investors Invest in Etana
JAKARTA, Indonesia, Sept. 14, 2021 /PRNewswire/ -- PT Etana Biotechnologies Indonesia (Etana)has secured a new round of investment led by Legend Capital along with Innovent Biologics, Inc. (Innovent) (HKEX: 01801), and a consortium led by UOB Venture Management (UOBVM). This round of funds will b...
2021-09-14 08:00
7700
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care Number of U.S. sites for the study has also been expanded RHB-107, a nov...
2021-09-13 19:00
7031
Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors
HOUSTON and SINGAPORE, Sept. 13, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets, today announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a Phas...
2021-09-13 17:00
2230
Everest Medicines Enters into Comprehensive Agreements with Providence Therapeutics to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Asia Emerging Markets
SHANGHAI, Sept. 13, 2021 /PRNewswire/ -- Everest Medicines Limited
2021-09-13 17:00
5731
Cytiva triples single-use consumables capacity in China
* Three new manufacturing lines were successfully launched in under ten months, with an additional eight new lines planned to launch in Q3 2022. * Sustain and secure the supply chain for customers in China and the broader region. * With the use of Fortem™ film, Cytiva helps customers speed...
2021-09-10 16:33
4151
Clover Biopharmaceuticals Receives Pharmaceutical Manufacturing Permit from Zhejiang Medical Products Administration to Produce COVID-19 Vaccine
CHENGDU, China, Sept. 9, 2021 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
(Clover)
2021-09-09 19:51
3264
Gan & Lee Pharmaceuticals to present data at the 57th Annual European Association for the Study of Diabetes Meeting
BEIJING and BRIDGEWATER, N. J., Sept. 9, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is excited to present positive data from five abstracts which will be featured as short oral discussions at the 57th Annual European Ass...
2021-09-09 15:00
3383
WCLC 2021 | Mini Oral - Ascentage Pharma Announces Latest Data of Its Investigational Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) Combined with Osimertinib in Patients with EGFR TKI-Resistant Non-Small Cell Lung Cancer
SUZHOU, China, and ROCKVILLE, MD., Sept 9, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today reported the Phase Ib results of the dual Bcl-2/Bcl-xL inhi...
2021-09-09 08:26
7173
CStone presents registrational bridging study data for GAVRETO® (pralsetinib) highlighting efficacy and safety in Chinese patients with advanced RET fusion-positive non-small cell lung cancer at IASLC WCLC 2021
SUZHOU, China, Sept. 9, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines, today announced that efficacy and safety data from a...
2021-09-09 08:00
4773
HaemaLogiX raises $10 million to advance multiple myeloma treatments
* HaemaLogiX completes a fully subscribed $10 million share placement and welcomes Platinum Asset Management as core new institutional investor within its Platinum International Health Care Fund * Funding underpins HaemaLogiX's drug development pipeline, targeting multiple myeloma - the sec...
2021-09-09 05:00
2865
Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets
SHANGHAI, Sept. 8, 2021 /PRNewswire/ -- Huadong Medicine (SZ.000963) and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the companies have entered into a co-development partnership to accelerate the discovery of brea...
2021-09-08 20:08
5053
Yiling Pharmaceutical's Yishen Yangxin Anshen Tablets Granted Drug Certificate
SHIJIAZHUANG, China, Sept. 8, 2021 /PRNewswire/ -- Yiling Pharmaceutical recently announced that its newly-developed drug Yishen Yangxin Anshen Tablet had been granted official drug certificate byChina's National Medical Products Administration (NMPA). With the functions of reinforcing kidney, n...
2021-09-08 12:28
3425
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors
NORTH BRUNSWICK, New Jersey and HANGZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple ...
2021-09-08 11:04
3193
Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China
SAN FRANCISCO and SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2021-09-08 08:00
8443
Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients
DURHAM, N.C. and BEIJING, Sept. 7, 2021 /PRNewswire/ -- Brii Biosciences
2021-09-07 19:04
5973
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
- COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive process which occurs in patients with chronic kidney disease (CKD) and can ultimately lead to ...
2021-09-07 19:00
3713
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021
- Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients aged ≥ 65 years - Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placeb...
2021-09-07 18:00
4623
Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer
BENGALURU, India, Sept. 7, 2021 /PRNewswire/ -- Today, Jubilant Biosys Limited
announced the appointment ofGiuliano Perfetti as its Chief Executive Officer.
2021-09-07 16:11
6303
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 314 media titles]
2026-08-27 10:25
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 309 media titles]
2026-09-02 08:30Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 309 media titles]
2026-09-02 12:17
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 302 media titles]
2026-09-01 11:00
Most Read
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
17500